Opposing effects of dexamethasone, agrin and sugammadex on functional innervation and constitutive secretion of IL-6 in in vitro innervated primary human muscle cells

• Published in: Neuroscience letters Vol. 549; pp. 186 - 190
• Main Authors: Rezonja, K., Lorenzon, P., Mars, T.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 09.08.2013
• Subjects: Agrin; Agrin - pharmacology; Animals; Dexamethasone; Dexamethasone - pharmacology; Drug Interactions; gamma-Cyclodextrins - pharmacology; Humans; Interleukin 6; Interleukin-6 - secretion; Muscle, Skeletal - drug effects; Muscle, Skeletal - innervation; Muscle, Skeletal - secretion; Myoblasts - drug effects; Neuromuscular junction; Neuromuscular Junction - drug effects; Neuromuscular Junction - secretion; Rats; Rats, Sprague-Dawley; Sugammadex; Interleukin 6; Dexamethasone; Sugammadex; Agrin; Neuromuscular junction
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2013.06.014

•Dexamethasone affects functional innervation and IL-6 release in in vitro model of innervated human muscle cell.•Agrin and dexamethasone have opposite effect of functional innervation.•Dexamethasone chemically interacts with sugammadex.•Chemical interaction between dexamethasone and sugammadex results in decreased IL-6 release. Neuromuscular junction development is the key process required for successful neuromuscular transmission and functional innervation of skeletal muscle fibres. Various substances can influence these processes, some of which are in common use in clinical practice. In the present study, the effects of the potentially new therapeutic agent agrin were followed, along with the widely used glucocorticoid dexamethasone. The in vitro experimental model used was functional innervation and constitutive interleukin 6 (IL-6) secretion of human muscle cells. Additionally, the selective relaxant binding agent sugammadex and its possible interaction with dexamethasone were followed. Dexamethasone impaired functional innervation while agrin had opposing effects. Furthermore, based on interference with IL-6 secretion, we show potential (chemical) interactions between dexamethasone and sugammadex. The physiological effects of this interaction should be taken into consideration under clinical conditions where these two drugs might be applied simultaneously.